BiotechTube

MK-3475 + ASG-22CE

Phase 2Recruiting
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Bladder Cancer

Conditions

Bladder Cancer

Trial Timeline

Oct 1, 2023 → Sep 30, 2027

NCT ID
NCT05879653

About MK-3475 + ASG-22CE

MK-3475 + ASG-22CE is a phase 2 stage product being developed by Astellas Pharma for Bladder Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05879653. Target conditions include Bladder Cancer.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT05879653Phase 2Recruiting

Competing Products

20 competing products in Bladder Cancer

See all competitors
ProductCompanyStageHype Score
pegylated liposomal doxorubicin (PLD) + PD-1CSPC Pharmaceutical Group LimitedPhase 2
51
EG-70 (phase 1) + EG-70 (phase 2)enGenePhase 1/2
33
mirabegron + solifenacinAstellas PharmaApproved
85
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Enfortumab vedotinAstellas PharmaPhase 1
33
Mirabegron + PlaceboAstellas PharmaApproved
85
SolifenacinAstellas PharmaApproved
85
Mirabegron + Tolterodine + Placebo to Mirabegron + Placebo to TolterodineAstellas PharmaPhase 3
77
solifenacin succinateAstellas PharmaPhase 3
77
SolifenacinAstellas PharmaPre-clinical
23
BetanisAstellas PharmaPre-clinical
23
SolifenacinAstellas PharmaApproved
85
SolifenacinAstellas PharmaPhase 2
52
Mirabegron + Tolterodine ERAstellas PharmaApproved
85
mirabegron + solifenacin + darifenacin + imidafenacin + tolterodine + oxybutynin + trospium + fesoterodine + propiverineAstellas PharmaPre-clinical
23
Enfortumab vedotin + PembrolizumabAstellas PharmaPhase 2
52
Enfortumab Vedotin + PembrolizumabAstellas PharmaPhase 2
52
Alpha blocker + placebo + solifenacinAstellas PharmaApproved
85
warfarin + YM178Astellas PharmaPhase 1
33
Pembrolizumab + Enfortumab vedotin (EV) + Gemcitabine + CisplatinAstellas PharmaPhase 3
77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85